[Structural valve deterioration after transcatheter aortic valve replacement: a research update]
- PMID: 40304105
- PMCID: PMC12062941
- DOI: 10.3724/zdxbyxb-2024-0470
[Structural valve deterioration after transcatheter aortic valve replacement: a research update]
Abstract
Structural valve deterioration (SVD) refers to intrinsic and irreversible pathological changes in the components of prosthetic heart valves, manifesting as fibrosis, calcification, wear and tear, loosening, as well as strut fracture or deformation of the valve framework. These changes ultimately lead to valve stenosis and/or regurgitation.The mechanisms may be related to mechanical stress, immune response and abnormal calcium-phosphorus metabolism. Studies have shown that risk factors for SVD include patient factors (such as age, underlying cardiovascular disease and comorbidities), valve factors (such as material properties, processing techniques, and valve type), and surgical factors (such as valve injury, suboptimal stent expansion, and irregular stent release morphology). Clinical imaging assessment of SVD demonstrates complementary advantages among echocardiography, multi-detector spiral CT and cardiac magnetic resonance imaging, with distinct diagnostic objectives. The primary management strategies for SVD after trans-catheter aortic valve replacement (TAVR) include drug therapy, redo-TAVR, surgical aortic valve replacement (SAVR) and the novel SURPLUS technique. Among them, redo-TAVR has become a common method because of its minimally invasive nature, but it is still necessary to further clarify the patient indications and optimize the surgical strategy. SAVR is reserved for young, low-risk patients; SURPLUS combines the advantages of SAVR and TAVR, making it suitable for cases where redo-TAVR is unfeasible or contraindicated, while the risk of SAVR is excessively high. This article reviews the latest progress of SVD following TAVR treatment to provide reference for research into the durability of bioprosthetic valve and clinical intervention of SVD.
结构性瓣膜退化(SVD)是人工心脏瓣膜的自身组件发生内在不可逆的病理改变,表现为瓣膜纤维化、钙化、磨损、撕裂、松弛以及支架断裂或变形等,最终导致瓣膜狭窄和/或反流。经导管主动脉瓣置换术(TAVR)后出现SVD的发生机制可能与机械应力、免疫反应及钙磷代谢异常有关。TAVR后SVD的危险因素包括患者因素(如年龄、心血管基础疾病及其合并症)、瓣膜因素(如材料、处理方式、类型)和手术因素(如瓣膜损伤、支架扩张不良、支架释放形态不规则)。临床上影像学评估TAVR后SVD时,超声心动图、多排螺旋计算机断层扫描和心脏磁共振成像各有优势,评估目的也有不同。主要应对策略包括药物治疗、再次TAVR、外科主动脉瓣置换术(SAVR)及SURPLUS术。再次TAVR因其微创性成为常用方法,但仍需进一步明确患者适应证和优化手术策略;SAVR适用于年轻、低风险患者;SURPLUS术则结合了SAVR和TAVR的优点,适用于再次TAVR不可行或有禁忌证,同时SAVR风险过高者。本文就SVD在TAVR治疗背景中的最新研究进展进行综述,以期为生物瓣耐久性研究和临床干预SVD提供参考。.
Keywords: Aortic valve; Bioprosthetic valve; Review; Structural valve deterioration; Transcatheter aortic valve replacement.
Conflict of interest statement
所有作者均声明不存在利益冲突
The authors declare that there is no conflict of interests
Similar articles
-
Aortic Regurgitation, Time to Aortic Valve Reintervention, and Mortality in Degenerated Trifecta Versus Non-Trifecta Bioprosthesis.Am J Cardiol. 2024 Jun 1;220:49-55. doi: 10.1016/j.amjcard.2024.03.033. Epub 2024 Apr 4. Am J Cardiol. 2024. PMID: 38580038
-
Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk.J Am Coll Cardiol. 2019 Feb 12;73(5):546-553. doi: 10.1016/j.jacc.2018.10.083. J Am Coll Cardiol. 2019. PMID: 30732707 Clinical Trial.
-
Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial.J Am Coll Cardiol. 2020 Oct 20;76(16):1830-1843. doi: 10.1016/j.jacc.2020.08.049. J Am Coll Cardiol. 2020. PMID: 33059828 Clinical Trial.
-
A systematic review on durability and structural valve deterioration in TAVR and surgical AVR.Acta Cardiol. 2021 Nov;76(9):921-932. doi: 10.1080/00015385.2020.1858250. Epub 2020 Dec 11. Acta Cardiol. 2021. PMID: 33302806
-
Transcatheter Aortic Valve-in-Valve Procedure in Patients with Bioprosthetic Structural Valve Deterioration.Methodist Debakey Cardiovasc J. 2017 Jul-Sep;13(3):132-141. doi: 10.14797/mdcj-13-3-132. Methodist Debakey Cardiovasc J. 2017. PMID: 29743998 Free PMC article. Review.
References
-
- NISHIMURA R A, OTTO C M, BONOW R O, et al. . 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2017, 70(2): 252-289. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources